dupilumab (Dupixent)

following a full submission assessed under the orphan equivalent medicine process:

dupilumab (Dupixent®) is accepted for use within NHSScotland.

Indication under review: for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.

In two double-blind, randomised, phase III studies, dupilumab treatment resulted in statistically and clinically significant improvements in the severity of pruritus (measured by the reduction in Worst-Itch Numeric Rating Scale [WI-NRS] by ≥4 points from baseline to week 24) in patients with PN, compared with placebo.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.